Aroa Biosurgery Ltd

Aroa Biosurgery has a current ratio of 6.62, indicating strong short-term liquidity, but its operating cash flow is negative at -2.57 million NZD, and free cash flow is also negative at -2.57 million NZD, suggesting ongoing cash burn. The company's debt-to-equity ratio is 0.07, reflecting a conservative capital structure with minimal leverage. Total liabilities amount to 15.79 million NZD, while total equity is 93.09 million NZD, indicating a strong equity base. The company's profitability is weak, with a return on equity of -4.1% and a return on assets of -3.5%, both significantly below the industry median for medical equipment and supplies firms. Gross profit is 72.61 million NZD, but operating income is negative at -2.92 million NZD, and net income is also negative at -3.81 million NZD, indicating operational inefficiencies. Aroa Biosurgery's revenue is concentrated in a few key products, including Endoform, Myriad Matrix, and Symphony, which are used in wound healing and soft tissue reconstruction. The company's geographic exposure is primarily in New Zealand and Australia, with limited international diversification. This concentration may expose the company to regional economic and regulatory risks. The company's revenue for the latest period is 84.70 million NZD, but there is no clear indication of growth in the near term. Analysts have provided a mean price target of 1.09 NZD, with a median of 1.12 NZD, suggesting limited upside potential. The mean recommendation is 1.67, indicating a generally positive outlook, but the absence of "hold" or "sell" ratings suggests a cautious stance. Aroa Biosurgery faces several risk factors, including liquidity concerns due to negative net cash after subtracting total debt. The company's dilution risk is currently low, with no significant dilution expected in the near term. However, the company's negative operating and free cash flows may necessitate future financing, which could lead to share dilution. Recent events include the continued development and distribution of its ECM-based products, with a focus on expanding its product portfolio and market reach. The company has also been working on improving its operational efficiency to reduce losses and improve profitability.